ArticleJournal of cellular and molecular medicine2022
Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.
Article in Journal of cellular and molecular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- "Clinical and radiological evaluation of periodontal intrabony defects treated with DFDBA and 1% melatonin gel and its effect on RANKL and OPG in gingival crevicularfluid - a randomized controlled trial".Clinical oral investigations · 2025Trial
- Maternal Sleep Quality and Early-Life Epigenetic Programming of Bone-Related Genes in Neonatal Cord Blood: Findings from the PERSIAN Birth Cohort, Isfahan.Calcified tissue international · 2026Article
- Relationship Between Serum Melatonin Levels and Bone Mineral Density in Postmenopausal Women with Type 2 Diabetes Mellitus.Clinical medicine insights. Endocrinology and diabetes · 2026Article
- The circadian-melatonin axis in breast cancer metastasis: molecular mechanisms, organ-specific metastatic niches, and therapeutic opportunities.Frontiers in endocrinology · 2026Review
- Role of microRNA in Diabetic Osteoporosis.Molecular biotechnology · 2025Review
- Melatonin alleviates sodium sulfite-induced osteoporosis in mice via suppression of the ferroptosis pathway.Apoptosis : an international journal on programmed cell death · 2025Article
- Local application of melatonin associated or not to xenogeneic material, in critical defects of rat calvaria.Acta odontologica latinoamericana : AOL · 2024Article
- Angelicin improves osteoporosis in ovariectomized rats by reducing ROS production in osteoclasts through regulation of the KAT6A/Nrf2 signalling pathway.Chinese medicine · 2024Article
- Target Role of Monocytes as Key Cells of Innate Immunity in Rheumatoid Arthritis.Diseases (Basel, Switzerland) · 2024Review
- Melatonin and bone-related diseases: an updated mechanistic overview of current evidence and future prospects.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023Review
- mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia.International journal of molecular sciences · 2023Review
- Leptin and melatonin's effects on OVX rodents' bone metabolism.Frontiers in endocrinology · 2023Article
- Melatonin inhibits osteoclastogenesis via RANKL/OPG suppression mediated by Rev-Erbα in osteoblasts.Journal of cellular and molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic osteoporosis is secondary osteoporosis and a serious complication of diabetes with a high incidence rate and poor prognosis. The specific mechanism of diabetic osteoporosis is unclear, and prevention and treatment options are limited. Recently, melatonin has been found to prevent and treat diabetic osteoporosis. Herein, we investigated the mechanism whereby melatonin inhibits osteoclastogenesis and identified a new target for osteoporosis treatment. We established an in vitro osteoblast-osteoclast co-culture system as a diabetic osteoporosis model. Osteoclastogenesis was determined using tartrate-resistant acid phosphatase staining and cathepsin K expression. Real-time PCR was used to ascertain expression of microRNA mir-882, targeting Rev-Erbα. Western blotting was performed to detect the expression of Rev-Erbα, receptor activator of NF-kB ligand (RANKL), and osteoprotegerin (OPG), and ELISA was utilized to analyse the secreted form of RANKL. High glucose promoted osteoclastogenesis and elevated the RANKL/OPG ratio in osteoblasts, while melatonin reversed these effects. High glucose inhibited Rev-Erbα expression, while melatonin promoted its expression. Conversely, high glucose promoted mir-882 expression, while melatonin inhibited it. We infer that melatonin inhibits RANKL expression in osteoblasts via the mir-882/Rev-Erbα axis, thus inhibiting osteoclastogenesis. Our findings provide insights into diabetic osteoporosis and identify a new therapeutic target for osteoporosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.